Business Description
Anavex Life Sciences Corp
NAICS : 325412
SIC : 8731
ISIN : US0327973006
Total Employee Number:
34Description
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.95 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4.2 | |||||
3-Year EPS without NRI Growth Rate | 4.3 | |||||
3-Year FCF Growth Rate | -13.3 | |||||
3-Year Book Growth Rate | -15.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.84 | |||||
9-Day RSI | 36.49 | |||||
14-Day RSI | 39.38 | |||||
3-1 Month Momentum % | -26.05 | |||||
6-1 Month Momentum % | -49.54 | |||||
12-1 Month Momentum % | -78.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 20.87 | |||||
Quick Ratio | 20.87 | |||||
Cash Ratio | 20.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | -16.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -38.18 | |||||
ROA % | -34.41 | |||||
ROIC % | -1832.98 | |||||
3-Year ROIIC % | -61.6 | |||||
ROCE % | -38.22 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 2.87 | |||||
PB Ratio | 1.75 | |||||
Price-to-Tangible-Book | 1.74 | |||||
EV-to-EBIT | -2.24 | |||||
EV-to-EBITDA | -2.24 | |||||
EV-to-Forward-Revenue | 0.64 | |||||
EV-to-FCF | -2.63 | |||||
| Price-to-Net-Current-Asset-Value | 1.74 | |||||
| Price-to-Net-Cash | 1.77 | |||||
Earnings Yield (Greenblatt) % | -44.64 | |||||
FCF Yield % | -15.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anavex Life Sciences Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.404 | ||
| Beta | 2.5639 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 84.85 | ||
| 14-Day RSI | 39.38 | ||
| 14-Day ATR (€) | 0.085741 | ||
| 20-Day SMA (€) | 2.155275 | ||
| 12-1 Month Momentum % | -78.58 | ||
| 52-Week Range (€) | 1.93 - 11.505 | ||
| Shares Outstanding (Mil) | 92.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anavex Life Sciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anavex Life Sciences Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2026-11-25 08:30 | In 129 days | ||
| Annual report for 2026 | 2026-11-25 | In 128 days | ||
| Fourth quarter earnings results for 2026 | 2026-11-25 | In 128 days | ||
| Third quarter earnings conference call for 2026 | 2026-08-12 08:30 | In 24 days | ||
| Third quarter earnings results for 2026 | 2026-08-12 | In 23 days | ||
| General meeting for 2026 | 2026-07-22 10:00 | In 3 days | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 13:30 | 2.29 (+0.00%) | ||
| Citizens Life Sciences Conference | 2026-03-10 11:55 | 3.85 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 11:50 | 3.96 (+8.80%) | ||
| First quarter earnings conference call for 2026 | 2026-02-09 08:30 | 3.40 (+9.54%) |
Show
Entries
Anavex Life Sciences Corp Frequently Asked Questions
What is Anavex Life Sciences Corp(FRA:12X1)'s stock price today?
The current price of FRA:12X1 is €1.93. The 52 week high of FRA:12X1 is €11.51 and 52 week low is €1.93.
When is next earnings date of Anavex Life Sciences Corp(FRA:12X1)?
The next earnings date of Anavex Life Sciences Corp(FRA:12X1) is 2026-08-12 Est..
Does Anavex Life Sciences Corp(FRA:12X1) pay dividends? If so, how much?
Anavex Life Sciences Corp(FRA:12X1) does not pay dividend.
Press Release
Articles on Anavex Life Sciences Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers